Contraceptive Choice and Use of Dual Protection Among Women Living with HIV in Canada: Priorities for Integrated Care

2017 ◽  
Vol 49 (4) ◽  
pp. 223-236 ◽  
Author(s):  
Angela Kaida ◽  
Sophie Patterson ◽  
Allison Carter ◽  
Mona Loutfy ◽  
Erin Ding ◽  
...  
Keyword(s):  
Integrated Care ◽  
Women Living With Hiv ◽  
Dual Protection ◽  
Contraceptive Choice ◽  
Living With Hiv

(Dis)integrated Care: Barriers to Health Care Utilization for Trans Women Living With HIV

2017 ◽  
Vol 28 (5) ◽  
pp. 708-722 ◽  
Author(s):  
Lauren Munro ◽  
Zack Marshall ◽  
Greta Bauer ◽  
Rebecca Hammond ◽  
Caleb Nault ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Utilization ◽  
Integrated Care ◽  
Care Utilization ◽  
Barriers To Health Care ◽  
Women Living With Hiv ◽  
Trans Women ◽  
Living With Hiv ◽  
Barriers To Health

scholarly journals Dual Protection and Dual Methods in Women Living with HIV: The Brazilian Context

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Kiyomi Tsuyuki ◽  
Regina María Barbosa ◽  
Adriana de Araujo Pinho
Keyword(s):  
Condom Use ◽  
Unintended Pregnancy ◽  
Consistent Condom ◽  
Consistent Condom Use ◽  
Cross Sectional ◽  
Women Living With Hiv ◽  
Dual Methods ◽  
Dual Protection ◽  
Reversible Method ◽  
Living With Hiv

The cooccurrence of HIV and unintended pregnancy has prompted a body of work on dual protection, the simultaneous protection against HIV and unintended pregnancy. This study examines dual protection and dual methods as a risk-reduction strategy for women living with HIV. Data are from a cross-sectional sample of HIV-positive women attended in Specialized STI/AIDS Public Health Service Clinics in 13 municipalities from all five regions of Brazil 2003-2004 (N=834). Descriptive techniques and logistic regression were used to examine dual protection among women living with HIV. We expand the definition of dual protection to include consistent condom use and reversible/irreversible contraceptive methods, we test the dual methods hypothesis that women who use dual methods will use condoms less consistently than women who use only condoms, and we identify predictors of dual protection. Dual protection is common in our sample. Women who use dual methods have lower odds of consistent condom use than women who only use condoms. Among dual method users, we find that women who use an irreversible method use condoms more consistently than women who use a reversible method. Women on ART and with an HIV-serodiscordant partner have greater odds of consistent condom use than their counterparts.

Women living with HIV breaking the silence in the Mena region

2012 ◽  
Author(s):  
Hind Khatib-Othman ◽  
Shereen el-Feki ◽  
Kamal Mountasser ◽  
Hend Sabry ◽  
Rita Wahab
Keyword(s):  
Mena Region ◽  
Women Living With Hiv ◽  
Living With Hiv

The Complexity of Work for Women who are HIV Positive: A Case Study in DKI Jakarta

2018 ◽  
Vol 23 (4) ◽  
pp. 203
Author(s):  
Andi Nur Faizah
Keyword(s):  
Qualitative Method ◽  
Family Members ◽  
Hiv Positive ◽  
Difficult Situation ◽  
Women Living With Hiv ◽  
Hiv Positive Women ◽  
And Gender ◽  
Gender Categories ◽  
Living With Hiv

<p>The phenomenon of HIV-AIDS transmission places women in a difficult situation. The loss of family members such as husbands due to AIDS leaves women living with HIV positive in a struggle to access sources of livelihood. The condition of themselves as PLWHA, concerns about being stigmatized, caring for family members, and earning a living are the burdens of life they have to face. In this regard, this paper explores the complexity of the work of HIV-positive women. This study uses a qualitative method with a feminist perspective to get a complete picture of the livelihood of HIV-positive women. Based on interviews with five HIV-positive women, the findings found a link between social, identity, and gender categories that affect their livelihoods. HIV-positive women also transform themselves into their “normal” self by pretending to be healthy, able to work, have quality, and be independent. This is done as a form of resistance to the stigma attached to PLWHA.</p><p> </p><p> </p>

Pharmacokinetics, Placental and Breast Milk Transfer of Antiretroviral Drugs in Pregnant and Lactating Women Living with HIV

2019 ◽  
Vol 25 (5) ◽  
pp. 556-576 ◽  
Author(s):  
E.M. Hodel ◽  
C. Marzolini ◽  
C. Waitt ◽  
N. Rakhmanina
Keyword(s):  
Breast Milk ◽  
Protease Inhibitors ◽  
Drug Class ◽  
Drug Transporters ◽  
Maternal Plasma ◽  
Antiretroviral Drugs ◽  
Physiological Changes ◽  
Women Living With Hiv ◽  
Living With Hiv ◽  
In Pregnancy

Background:Remarkable progress has been achieved in the identification of HIV infection in pregnant women and in the prevention of vertical HIV transmission through maternal antiretroviral treatment (ART) and neonatal antiretroviral drug (ARV) prophylaxis in the last two decades. Millions of women globally are receiving combination ART throughout pregnancy and breastfeeding, periods associated with significant biological and physiological changes affecting the pharmacokinetics (PK) and pharmacodynamics (PD) of ARVs. The objective of this review was to summarize currently available knowledge on the PK of ARVs during pregnancy and transport of maternal ARVs through the placenta and into the breast milk. We also summarized main safety considerations for in utero and breast milk ARVs exposures in infants.Methods:We conducted a review of the pharmacological profiles of ARVs in pregnancy and during breastfeeding obtained from published clinical studies. Selected maternal PK studies used a relatively rich sampling approach at each ante- and postnatal sampling time point. For placental and breast milk transport of ARVs, we selected the studies that provided ratios of maternal to the cord (M:C) plasma and breast milk to maternal plasma (M:P) concentrations, respectively.Results:We provide an overview of the physiological changes during pregnancy and their effect on the PK parameters of ARVs by drug class in pregnancy, which were gathered from 45 published studies. The PK changes during pregnancy affect the dosing of several protease inhibitors during pregnancy and limit the use of several ARVs, including three single tablet regimens with integrase inhibitors or protease inhibitors co-formulated with cobicistat due to suboptimal exposures. We further analysed the currently available data on the mechanism of the transport of ARVs from maternal plasma across the placenta and into the breast milk and summarized the effect of pregnancy on placental and of breastfeeding on mammal gland drug transporters, as well as physicochemical properties, C:M and M:P ratios of individual ARVs by drug class. Finally, we discussed the major safety issues of fetal and infant exposure to maternal ARVs.Conclusions:Available pharmacological data provide evidence that physiological changes during pregnancy affect maternal, and consequently, fetal ARV exposure. Limited available data suggest that the expression of drug transporters may vary throughout pregnancy and breastfeeding thereby possibly impacting the amount of ARV crossing the placenta and secreted into the breast milk. The drug transporter’s role in the fetal/child exposure to maternal ARVs needs to be better understood. Our analysis underscores the need for more pharmacological studies with innovative study design, sparse PK sampling, improved study data reporting and PK modelling in pregnant and breastfeeding women living with HIV to optimize their treatment choices and maternal and child health outcomes.

Sign in / Sign up

Export Citation Format

Share Document